Bial and Eisai report positive results from Phase II trial of Zebinix for epilepsy

Bial and Eisai have reported a positive outcome from a Phase II clinical trial (Study 208) of Zebinix (eslicarbazepine acetate) in children with focal-onset epilepsy.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news